SCHEMBL4147375

SCHEMBL4147375

CCOC(=O)c1cnc([S+](C)[O-])nc1Oc1ccc(C(C)C)cc1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 4/20 0.51
POLB P06746 2/20 0.51
CYP2C9 P11712 2/20 0.50
CYP2C19 P33261 2/20 0.50
L3MBTL1 Q9Y468 2/20 0.50
ALDH1A1 P00352 5/20 0.49
LMNA P02545 4/20 0.49
NPC1 O15118 3/20 0.41
RAB9A P51151 2/20 0.41
MAPK1 P28482 1/20 0.39
NPBWR1 P48145 1/20 0.39
MAPT P10636 3/20 0.38
SMN1; SMN2 Q16637 2/20 0.38
GPR55 Q9Y2T6 1/20 0.38
HTT P42858 1/20 0.38
NPSR1 Q6W5P4 2/20 0.38
KMT2A Q03164 1/20 0.38
GAA P10253 1/20 0.38
HSP90AA1 P07900 1/20 0.37
HSD17B10 Q99714 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4140368 0.81 ALDH1A1 (0.56) CYP1A2POLBCYP2C9CYP2C19L3MBTL1
SCHEMBL25209893 0.80 CYP1A2 (0.43) CYP1A2POLBCYP2C9CYP2C19L3MBTL1
SCHEMBL25215754 0.80 ALDH1A1 (0.43) CYP1A2POLBCYP2C9CYP2C19L3MBTL1
SCHEMBL25436320 0.79 ALDH1A1 (0.45) CYP1A2POLBCYP2C9CYP2C19L3MBTL1
SCHEMBL25252195 0.77 KDM4E (0.40) CYP1A2POLBCYP2C9CYP2C19L3MBTL1
SCHEMBL15732434 0.76 PDE5A (0.39) CYP1A2POLBCYP2C9CYP2C19ALDH1A1
SCHEMBL4147345 0.75 KDM4E (0.50) CYP1A2POLBCYP2C9CYP2C19L3MBTL1
SCHEMBL4146288 0.73 MEN1 (0.38) CYP1A2POLBCYP2C9CYP2C19L3MBTL1
SCHEMBL4154386 0.71 L3MBTL1 (0.51) L3MBTL1LMNANPC1RAB9AMAPT
SCHEMBL14653206 0.70 PDE5A (0.46)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090227587-A1 Pyrimidines as inhibitors of phosphoinositide-3-kinases (PI3K) WARNER-LAMBERT COMPANY LLC 2009-09-10 US disclosed
EP-1682532-B1 PYRIMIDINES AS INHIBITORS OF PHOSPHOINOSITIDE-3-KINASES (PI3K) WARNER LAMBERT CO (US) 2007-06-27 EP disclosed
EP-1682532-A1 PYRIMIDINES AS INHIBITORS OF PHOSPHOINOSITIDE-3-KINASES (PI3K) Warner-Lambert Company LLC (US) 2006-07-26 EP disclosed
WO-2005042519-A1 PYRIMIDINES AS INHIBITORS OF PHOSPHOINOSITIDE -3-KINASES (PI3K) WARNER-LAMBERT COMPANY LLC (US) 2005-05-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090227587-A1 Pyrimidines as inhibitors of phosphoinositide-3-kinases (PI3K) PIK3CA, PIK3CD, PIK3R5 CYP1A2 1815/4885POLB 862/4885CYP2C9 881/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.